Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01838564 · ClinicalTrials.gov registry record · NA

The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology

A NA study of Quality of Life and Palliative Care, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
104
Enrollment target
4
Study locations

NCT01838564: Completed NA study of Quality of Life and Palliative Care, sponsored by Dana-Farber Cancer Institute.

NCT01838564 is a NA study of Quality of Life and Palliative Care that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 104 participants, below the 452-participant average among 107 other Quality of Life trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01838564, a NA study of Quality of Life and Palliative Care, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target
4
Study locations

Study Summary

Over 50% of children dying from cancer still suffer from symptoms that could be effectively alleviated. The purpose of the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study was to evaluate whether providing feedback to families and providers about how the child is feeling improved child distress and quality of life (QoL) in children with advanced cancer. PediQUEST is a computerized survey that asks the child and/or parents how the child has been feeling, i.e. whether the child had any physical or emotional symptoms, as well as how other aspects of life, such as school and friends, are going. After the survey is complete a report that summarizes patient/parent answers is printed. When a child reports moderate to high distress from any symptom an email is automatically sent to the primary providers (oncologist, nurse, and psycho-social clinician as well as the pain and palliative care services) alerting them about the child's distress. In this study we evaluated whether using PediQUEST and providing printed reports to parents and providers reduced distress and improved quality of life in children with advanced cancer. In addition, we wanted to understand whether it was feasible to carry out a randomized controlled trial in children with advanced cancer. Finally, the data collected, will be used to describe the natural history of symptoms and quality of life as reported by the children. Children enrolled in the study (or their parents) were asked to complete a PediQUEST survey at most once a week. A random half of the children received the feedback intervention, i.e. patients, parents, and providers received printed reports (and emails if the child was in distress). The other half only completed the PediQUEST surveys and did not receive reports. We analyzed data collected over 20 weeks of follow-up to see whether receiving PediQUEST reports had any effect on child distress and quality of life.

Primary Outcome

Child distress-unrelieved symptoms will be assessed through the proportion of patients with unrelieved symptoms (any symptom/s reported as causing moderate to high distress or FPS-R score \>=8 in 2 consecutive PediQUEST evaluations)

Interventions

  • OTHER Routine Data collection
  • OTHER Feedback of patient-reported outcomes

Study Locations (4)

Massachusetts

  • Boston Children's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Pennsylvania

  • Children's Hospital of Philapdelphia - Philadelphia

Washington

  • Seattle Children's Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2004-11
Est. Completion 2010-06
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT01838564 record still lists

NCT01838564 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 452-participant average among 107 other Quality of Life trials with a reported enrollment target (77% lower).

The record links to 4 conditions, with Quality of Life appearing as the primary indexed condition, and to 2 interventions - of which Routine Data collection is the first listed.

NCT01838564 reports a single indexed study location in Massachusetts, Pennsylvania, Washington.

Frequently Asked Questions

What is clinical trial NCT01838564 about?

NCT01838564 is a clinical study titled "The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology". Over 50% of children dying from cancer still suffer from symptoms that could be effectively alleviated. The purpose of the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study was to evaluate whether providing feedback to families and providers about how the child is fee...

What is the current status of trial NCT01838564?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2004-11. Estimated completion is 2010-06.

What conditions does trial NCT01838564 study?

This clinical trial studies the following conditions: Quality of Life, Palliative Care, Pediatric Neoplasm, Outcome Assessment.

What interventions are being tested in trial NCT01838564?

The interventions under investigation include: Routine Data collection (OTHER), Feedback of patient-reported outcomes (OTHER).

Who is sponsoring clinical trial NCT01838564?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01838564 being conducted?

This trial has 4 study locations across Massachusetts, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Quality of Life

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01838564's enrollment target sits among peer trials

104 49th of 107 higher than 59 of 107 other Quality of Life trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Quality of Life trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01838564, the US trial registry maintained by the National Library of Medicine. NCT01838564 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.